Group One Trading LLC Sells 27,779 Shares of Enovis Corporation $ENOV

Group One Trading LLC lessened its holdings in shares of Enovis Corporation (NYSE:ENOV) by 92.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,334 shares of the company’s stock after selling 27,779 shares during the quarter. Group One Trading LLC’s holdings in Enovis were worth $53,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ENOV. Allspring Global Investments Holdings LLC increased its holdings in shares of Enovis by 11.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock valued at $20,086,000 after purchasing an additional 78,497 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. acquired a new stake in shares of Enovis in the fourth quarter valued at about $2,929,000. Impax Asset Management Group plc boosted its holdings in Enovis by 36.5% during the fourth quarter. Impax Asset Management Group plc now owns 424,130 shares of the company’s stock worth $11,299,000 after buying an additional 113,500 shares in the last quarter. Invenomic Capital Management LP boosted its holdings in Enovis by 6.2% during the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock worth $20,159,000 after buying an additional 44,048 shares in the last quarter. Finally, Bernzott Capital Advisors grew its position in Enovis by 47.4% during the first quarter. Bernzott Capital Advisors now owns 294,125 shares of the company’s stock worth $6,691,000 after buying an additional 94,529 shares during the period. Institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders bought 4,200 shares of company stock valued at $92,084. Insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ENOV. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. William Blair assumed coverage on Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Wednesday, July 8th. Finally, Zacks Research downgraded Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.71.

Enovis Stock Down 1.6%

ENOV stock opened at $26.12 on Friday. The company has a 50 day moving average price of $23.60 and a two-hundred day moving average price of $23.76. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock has a market capitalization of $1.50 billion, a P/E ratio of -1.31 and a beta of 1.39. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter in the previous year, the business earned $0.81 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts expect that Enovis Corporation will post 3.12 EPS for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.